semaglutide versus Comparison of body weight parameters for placebo Cardiovascular outcomes of semaglutide and

[1] [2] It belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists

In contrast, GLP-1RAs provide an effective alternative, achieving robust glycemic control with a lower risk of hypoglycemia and reduced variability 28

By addressing both structural support and cellular protection, this approach targets the root causes of skin aging rather than just masking symptoms

Understanding this distinction helps providers optimize dosing and set realistic expectations for each individual

That's the baseline of what a legitimate platform should provide - and Trimi provides it

10 Peruzzotti-JamettiLPluchinoS